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The detailed report by Timothy Harkin and colleagues1 of
an unusual case of respiratory illness eventually diagnosed
as COVID-19 raises issues about the role of imaging in the
management of the disease. The causative virus, severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
can result in lethal pneumonia, so might chest imaging
have a central role in the detection or management of
COVID-19? Is there a signature imaging appearance of the
virus that could alert radiologists to its presence?
Early literature describes so-called typical imaging
features of COVID-19 and reports high sensitivity for
detection of COVID-19 by CT. This typical appearance
of COVID-19 is peripheral or posterior ground glass and
consolidative opacities with lower-lung predominance.2
Notably, these features are similar to those described
previously for SARS-CoV and Middle East respiratory
syndrome-CoV.3 However, the studies that reported high
sensitivity of CT for detection of COVID-19 did not use
these typical features to determine whether a CT scan
is positive for disease, but rather used broad and nonspecific findings of any airspace process.4 This approach
represents a deviation from standard clinical practice,
with CT findings reported in a binary fashion as either
positive or negative without clear delineation of criteria.
Furthermore, the inclusion criteria for studies reporting
high sensitivity were not well described and potentially
reflect substantial selection bias of hospitalised patients
with pneumonia in a region with a high prevalence of
COVID-19. Early in the disease course or in asymptomatic
patients, CT has been shown to be normal in around half
of cases (in 20 [56%] of 36 cases reported by Bernheim
and colleagues,5 and 38 [46%] of 82 cases reported by
Inui and colleagues6). Although some clinicians have
advocated the use of CT as an adjunct to or in lieu of
RT-PCR in settings where testing capacity is insufficient,
this strategy would probably lead to false-negative results.
Where does this leave the radiologist or treating
physician? Imaging can range from normal to typically
abnormal for COVID-19. Furthermore, the so-called typical
findings have substantial overlap with other infectious
and non-infectious entities, including cryptogenic
and drug-related organising pneumonias, pulmonary
infarcts, and septic emboli. Although distinguishing these

entities might be possible on the basis of clinical history,
presentation clearly overlaps, and patients might have
more than one infection simultaneously.
Two groups recently proposed standardised CT
reporting guidelines: the Radiological Society of North
America (RSNA)7 and the Dutch Radiological Society.8
The aims of these reporting guidelines are to familiarise
all radiologists with the typical imaging findings of
COVID-19, and to decrease inter-radiologist variation
in the reporting of cases. Although these guidelines
do represent important contributions, they should be
applied with caution.
The first challenge for any reporting guideline system
is defining the appropriate clinical context. The Dutch
group calls its scheme the COVID-19 reporting and
data system (CO-RADS), analogous to the established
BI-RADS for breast cancer screening or Lung-RADS for
lung cancer screening proposed by the American College
of Radiology. When BI-RADS or Lung-RADS should be
applied is clear: in patients who are being screened for
breast or lung cancer, respectively. However, the specific
scenarios in which the RSNA reporting guidelines or
CO-RADS should apply are less clear. Do they apply to
patients with known COVID-19, suspected COVID-19,
no suspicion of COVID-19, negative COVID-19 testing,
or another known diagnosis that might explain
lung findings? Clearly, use in suspected cases is the
intended application, although many specialty societies
discourage CT use in this scenario.9 In suspected cases,
the authors of CO-RADS showed high diagnostic
accuracy for the 105 cases on which the reporting
system is based; notably, these were all symptomatic
patients.8 However, the applicability of the reporting
categories in either the RSNA guidelines or CO-RADS
is less clear in other clinical scenarios. For example, a
patient with Staphylococcus aureus bacteraemia and
peripheral opacities most probably has septic emboli;
should that case also be reported as having typical
features of COVID-19? Similar trouble arises when
attempting to apply these categories to patients with
known COVID-19, as with the case presented by Harkin
and colleagues;1 what should atypical manifestations
mean in that setting? Finally, how should one interpret
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and apply so-called typical features in a patient with
multiple negative COVID-19 tests?
The second challenge for a reporting system is its
effects on patient management. This issue is arguably
more important than the language radiologists use,
yet it has unfortunately not been addressed by either
set of guidelines. If we look to BI-RADS or Lung-RADS
for comparison, both include solid recommendations
for management of each assessment category (eg,
BI-RADS 3 and Lung-RADS 3 necessitate 6-month
follow-up imaging). Neither the RSNA guidelines nor
CO-RADS recommend or even suggest subsequent
patient management. This lack of guidance represents
an acknowledgment that RT-PCR is the one and only
approved method for diagnosis of COVID-19, as
per WHO recommendations.10 To re-emphasise, the
management of any patient with suspected COVID-19 is
one or both of RT-PCR testing and isolation, irrespective
of RSNA or CO-RADS category. Typical does not mean
specific for COVID-19.
CT remains a powerful diagnostic tool in the context
of COVID-19 and should be used to trouble-shoot
problematic cases like the one presented by Harkin
and colleagues. Clinicians are still in the early stages of
understanding COVD-19 and need to acknowledge the
shortcomings of research to date. CT has been studied
primarily in regions with a high prevalence of COVID-19,
but its performance in lower-prevalence environments
that we are likely to see in the coming months is not clear.
A well designed, cross-sectional study is needed to define
the sensitivity of typical CT findings and their specificity
when multiple other disease processes are at play.
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